We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RNA Helicase Promotes Growth of Ewing's Sarcoma

By Biotechdaily staff writers
Posted on 30 Jun 2006
Cancer researchers have found that the activity of the oncogenic protein EWS-FLI1, which is present in Ewing's sarcoma tumor cells, was enhanced by that of an RNA helicase found to be highly expressed in Ewing's sarcoma cell lines and patients' tumors.

Ewing's sarcoma occurs most frequently in male teenagers. More...
This cancer develops as the result of a translocation between chromosomes 11 and 22, which fuses the EWS gene of chromosome 22 to the FLI1 gene of chromosome 11. The fused genes produce the EWS-FLI1 fusion protein, which is only found in Ewing's sarcoma tumors.

Investigators at Georgetown University (Washington, DC, USA) sought co-factor proteins that might modulate the activity of EWS-FLI1 in order to find a means of chemically blocking this interaction and thereby slowing or stopping tumor growth.

They reported in the June 1, 2006, issue of Cancer Research that EWS-FLI1 specifically binds an RNA helicase A (RHA) peptide fragment comprising amino acids 630 to 1020. RHA is a member of the DEXH box helicase family of proteins, and is an integral component of protein complexes that regulate transcription and splicing.

"Proteins are three-dimensional structures, and the space between EWS-FLI1 and the helicase might be targetable by a small molecule that keeps the proteins apart,” explained first author Dr. Jeffrey Toretsky, associate professor of oncology and pediatrics at Georgetown University. "It could render EWS-FLI1 harmless while not affecting its partnering helicase protein. Understanding the molecules EWS-FLI1 interacts with may provide insights into similar diseases. Very little work has been done to study the functional partners of these translocation proteins, and this study may offer a new research approach.”



Related Links:
Georgetown University

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.